Zurich Cantonal Bank
CYCN icon

Zurich Cantonal Bank’s Cyclerion Therapeutics CYCN Stock Holding History

Zurich Cantonal Bank’s Portfolio CYCN Stock Details CYCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-42
Closed -$2K – 2549
2020
Q1 		$2K Hold
42
– – ﹤0.01% 2584
2019
Q4 		$2K Hold
42
– – ﹤0.01% 2590
2019
Q3 		$10K Hold
42
– – ﹤0.01% 2553
2019
Q2 		$10K Buy
+42
New +$11.9K ﹤0.01% 2566

Other funds holding CYCN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
MP
MFN Partners Boston, Massachusetts $4.77B AUM 72.29% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Zurich Cantonal Bank's CYCN Position: Q2 2020 in Review

Zurich Cantonal Bank sold out of Cyclerion Therapeutics (CYCN) in Q2 2020, closing a stake of 42 shares — an estimated $2K sold.

Zurich Cantonal Bank first reported a position in CYCN in Q2 2019 and held it in 4 quarters. The position peaked at $10K in Q3 2019. 74 funds tracked by Wall St. Rank hold CYCN as of Q2 2020.

  • Zurich Cantonal Bank reported no remaining Cyclerion Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Zurich Cantonal Bank sold 42 Cyclerion Therapeutics shares in Q2 2020, an estimated $2K.
  • Zurich Cantonal Bank first reported a position in Cyclerion Therapeutics in Q2 2019 and held it in 4 quarters.
  • Zurich Cantonal Bank's Cyclerion Therapeutics position peaked at $10K in Q3 2019.
  • 74 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q2 2020.

Based on Zurich Cantonal Bank's 13F filing for Q2 2020, filed 28 Jul 2020.